UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Re-live UEG Week 2026 on Gutflix Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

SHOULD WE PERFORM ROUTINE TRANSIENT ELASTOGRAPHY (FIBROSCAN®) TO ASSES LIVER FIBROSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE? (ONGOING STUDY)

Kaoutar Chahi 1, Siham Belhorma 1, Hajar Koulali 2, Zazour Abdelkrim 3, Zahi Ismaili 4, Ghizlane Kharrasse 5

Affiliations

1 CHU Mohammed Vi Oujda, Oujda, Morocco

2 Mohammed VI University Hospital, Oujda, Morocco

3 Mohammed VI University Hospital, Mohammed the First University, Oujda, Morocco

4 Medical School, Oujda, Morocco

5 Faculty of Medicine Oujda, Oujda, Morocco

Summary

AI Generated

A prospective study of 56 IBD patients using FibroScan found that 19.6% had significant liver fibrosis (≥F2), with age and female sex independently associated with higher liver stiffness.

In 56 IBD patients (43 Crohn disease, 13 ulcerative colitis), mean liver stiffness was 7 kPa, with 19.6% showing fibrosis values greater than F2 (≥8 kPa cutoff) and 80.3% below F2.
Liver stiffness showed no differences based on IBD type or BMI, but age and female sex were independently associated with higher liver stiffness.
The authors conclude that FibroScan is a non-invasive technique potentially useful for evaluation and follow-up of liver fibrosis in IBD patients.
This material is relevant for gastroenterologists managing IBD patients and considering non-invasive liver assessment strategies.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Hepatobiliary disease is one of the most common extra-intestinal manifestations of chronic inflammatory bowel disease (IBD), but the prevalence of liver disease in IBD patients remains poorly understood and may be underestimated due to the use of invasive methods such as liver biopsy for diagnosis. Ultrasound pulse elastometry (FibroScan®) is a direct, non-invasive and effective physical approach to assess liver fibrosis.

Aims & Methods

The objective of the study is to assess the prevalence of liver fibrosis in IBD patients using ultrasound pulse elastometry (FibroScan®).
This prospective study included 56 patients with chronic inflammatory bowel disease, epidemiological, clinical and therapeutic data were collected. Liver elasticity was assessed by ultrasound pulse elastometry (FibroScan®) performed by a single physician. The cutoff value for significant liver fibrosis was F ≥2: 8 kPa.

Results

In this study, 56 patients were included, 22 men and 34 women with a sex ratio M/F of 0.6, the mean age was 32.9 years old, 43 patients had CROHN disease, 13 patients had UC. The mean duration of disease progression was 4.7 years. The mean value of liver stiffness was 7 kPa. The median IQR was 0.7 with an average success rate of 100%. 80.3% of patients had a fibrosis value < F2, and 19.6% of patients had a fibrosis value > F2. There were no differences in liver stiffness (LS) depending on type of IBD. Age and female sex, however, were independently associated with a higher LS.

Conclusion

This study confirms the relatively high prevalence of fibrosis in IBD patients, there were no differences in liver stiffness (LS) depending on type of IBD or BMI. Age and female sex, however, were independently associated with a higher LS. , Fibroscan is a non-invasive and efficient technique, which can be potentially useful for evaluation and follow-up of liver fibrosis in IBD patients.

Conference

UEG Week Copenhagen 2023

Topics

IBD

Submission format

Abstract

Session

PP 05 IBD (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano

SHORT-TERM GAINS, LONG-TERM CHALLENGES: A PILOT RANDOMIZED CONTROLLED TRIAL FOR TIME-RESTRICTED FEEDING VERSUS CALORIC RESTRICTION IN SIGNIFICANT MASLD

Dan Yock Young

OPTIMIZING SCREENING STRATEGIES FOR REFERRAL OF ADVANCED STEATOTIC LIVER DISEASE FROM PRIMARY CARE

Paloma Lluch García

ENDOSCOPIC FEATURES OF HELICOBACTER PYLORI INFECTION: DIFFERENCES BETWEEN PPI-USERS AND NO USERS

Guido Manfredi

EFFICACY AND SAFETY OF ELOBIXIBAT COMPARED WITH VITAMIN E IN ADULTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE: A 12-WEEK RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL

Irsan Hasan

CELIAC INSIDER WEBSITE AS A TOOL TO IMPROVE CELIAC DISEASE DIAGNOSIS

Mercè Tena

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Targeting immunometabolism with medical therapies in IBD

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano 1

Affiliations

1 IRCCS Ospedale San Raffaele, Milan, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Barcelona 2026

Topics

Small Intestine & Nutrition Mechanisms & Personalised Medicine Immunology IBD

Session

Metabolic aspects of immunomodulatory IBD therapy

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano

SHORT-TERM GAINS, LONG-TERM CHALLENGES: A PILOT RANDOMIZED CONTROLLED TRIAL FOR TIME-RESTRICTED FEEDING VERSUS CALORIC RESTRICTION IN SIGNIFICANT MASLD

Dan Yock Young

OPTIMIZING SCREENING STRATEGIES FOR REFERRAL OF ADVANCED STEATOTIC LIVER DISEASE FROM PRIMARY CARE

Paloma Lluch García

ENDOSCOPIC FEATURES OF HELICOBACTER PYLORI INFECTION: DIFFERENCES BETWEEN PPI-USERS AND NO USERS

Guido Manfredi

EFFICACY AND SAFETY OF ELOBIXIBAT COMPARED WITH VITAMIN E IN ADULTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE: A 12-WEEK RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL

Irsan Hasan

CELIAC INSIDER WEBSITE AS A TOOL TO IMPROVE CELIAC DISEASE DIAGNOSIS

Mercè Tena

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

SHORT-TERM GAINS, LONG-TERM CHALLENGES: A PILOT RANDOMIZED CONTROLLED TRIAL FOR TIME-RESTRICTED FEEDING VERSUS CALORIC RESTRICTION IN SIGNIFICANT MASLD

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

SHORT-TERM GAINS, LONG-TERM CHALLENGES: A PILOT RANDOMIZED CONTROLLED TRIAL FOR TIME-RESTRICTED FEEDING VERSUS CALORIC RESTRICTION IN SIGNIFICANT MASLD

Katelyn Chiu 1, Sophia Lin Delu 1, Jonathan Lee 2, Mastura Binte Salim 3, Nur Halisah Jumat 3, Lei Pheng Yeo 3, Jazleen Leo 3, Melissa Tay 4, Siew Min Ang 4, Amy Tay Yuh Ling 3, Eunice Tan 1, Mark Muthiah 1, Seng Gee Lim 1, Bee Choo Tai 3, Su Lin Lim 4, Dan Yock Young 1

Affiliations

1 National University Hospital, Singapore, Singapore, Singapore

2 National University Health System, Singapore, Singapore, Singapore

3 National University of Singapore, Singapore, Singapore

4 National University Hospital, Singapore, Singapore

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Weight loss remains the cornerstone therapy for Metabolic dysfunction associated steatotic liver disease (MASLD), for which caloric restriction (CR) is an established strategy. Recently, time restricted feeding (TRF) which aligns food intake with circadian rhythms have shown promise in improving metabolic outcomes. However, comparative data on adherence and weight loss between conventional CR and TRF in MASLD remain limited.

Aims & Methods

We conducted a single-centre pilot randomized controlled trial comparing TRF with conventional CR in adults with significant MASLD fibrosis (defined by liver stiffness by vibration-controlled transient elastography≥7kPa). Forty participants were randomized 1:1 to either daily CR (control) or TRF with an 8-hour feeding window (8:00–16:00) while maintaining equivalent caloric restriction. Dietary adherence was tracked through digital food logs and structured nutritional reviews. Compliance was defined as ≥70% adherence to the prescribed caloric intake (and TRF window for the intervention group. Participants were followed up to 12 months with serial anthropometric and clinical chemistry measurements.

Results

Forty participants (mean age 48.2 ± 12.2 years; 67.5% make, 72.5% Chinese) were enrolled. Baseline metabolic and anthropometric parameters were similar between the two arms (BMI 31.2 vs 30.7 kg/m2, p =0.77; waist circumference 104.6 vs 102.3cm, p=0.59, CAP 315.7 vs 311.2 dB/m, p=0.68, HbA1c 6.2% vs 6.1%, p=0.77). Comorbidities were balanced (diabetes 30%, hypertension 50%, dyslipidaemia 67.5%).
TRF participants achieved greater weight loss than control from Month 1 through Month 6 (p<0.01), with a mean percentage loss at 6 months of -7.7 ± 5.0% versus -2.0 ± 4.9% (p=0.01). The difference attenuated at 12 months (-3.8 ± 4.4% vs -1.6 ± 5.3%, p=0.19), reflecting partial weight gain after the intervention period. Early caloric adherence was comparable between the groups but declined in the TRF arm after 3 months. In the multivariable analysis, TRF independently predicted greater weight loss (p<0.01). Higher caloric adherence correlated with incremental weight reduction (-5% adherence for each 10% weight increase, p<0.01) though the relationship differed by the intervention arm (interaction p<0.01).

Conclusion

TRF led to significantly short-term weight loss compared with standard caloric restriction, and was feasible among adults with significant MASLD. However, adherence waned over time, enforcing that sustained behaviour support is essential to maintain long-term benefits.

Event

UEG Week Barcelona 2026

Topics

Primary Care Hepatobiliary

Submission format

Abstract

Session

Steatotic liver disease: From screening and stigma to therapy

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano

SHORT-TERM GAINS, LONG-TERM CHALLENGES: A PILOT RANDOMIZED CONTROLLED TRIAL FOR TIME-RESTRICTED FEEDING VERSUS CALORIC RESTRICTION IN SIGNIFICANT MASLD

Dan Yock Young

OPTIMIZING SCREENING STRATEGIES FOR REFERRAL OF ADVANCED STEATOTIC LIVER DISEASE FROM PRIMARY CARE

Paloma Lluch García

ENDOSCOPIC FEATURES OF HELICOBACTER PYLORI INFECTION: DIFFERENCES BETWEEN PPI-USERS AND NO USERS

Guido Manfredi

EFFICACY AND SAFETY OF ELOBIXIBAT COMPARED WITH VITAMIN E IN ADULTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE: A 12-WEEK RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL

Irsan Hasan

CELIAC INSIDER WEBSITE AS A TOOL TO IMPROVE CELIAC DISEASE DIAGNOSIS

Mercè Tena

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

OPTIMIZING SCREENING STRATEGIES FOR REFERRAL OF ADVANCED STEATOTIC LIVER DISEASE FROM PRIMARY CARE

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

OPTIMIZING SCREENING STRATEGIES FOR REFERRAL OF ADVANCED STEATOTIC LIVER DISEASE FROM PRIMARY CARE

David Marti Aguado 1, Marta Hernandez Conde 2, Adela Pozo Giraldez 1, Rosa Murria 1, Enrique Rodríguez-Borja 1, Ana Perez 2, Elba Llop 3, Marta Lopez Gomez 4, Javier Abad 4, Jesus Manuel Rivera Esteban 2, Cristina Monton 1, Desamparados Escudero-Garcia 5, Isabel Pascual-Moreno 6, Arturo Carratalá-Calvo 1, Jose Luis Calleja 4, Paloma Lluch García 1

Affiliations

1 Clinic University Hospital of Valencia, INCLIVA Health Research Institute, Valencia, Spain

2 Puerta de Hierro University Hospital, Madrid, Spain

3 Gastroenterology, Hospital Puerta de Hierro, Madrid, Spain, Madrid, Spain

4 Hospital Universitario Puerta de Hierro, Pozuelo De Alarcon, Spain

5 University of Valencia, Valencia, Spain

6 Hospital Clinico Universitario, Valencia, Spain

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Clinical practice guidelines recommend a two-step strategy to identify patients with significant fibrosis among individuals at risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD) [1,2]. A significant challenge of implementing the guidelines is the limited resources of VCTE, given the reported high rate of false positives among intermediate-risk FIB-4 group.

Aims & Methods

The primary aim of this real-world study was to optimize referral pathways for individuals at risk of MASLD and ALD attending primary care. We conducted a prospective, multicenter, opportunistic screening study using a computerized clinical decision support system integrated into primary care workflows. Consecutive individuals at risk of steatotic liver disease (SLD) undergoing routine blood testing were screened using a FIB-4–based pathway. The target population where participants with indeterminate FIB-4 (1.3–2.67) who were invited to undergo a vibration-controlled transient elastography (VCTE). Alternative non-invasive tests (NITs)—Enhanced Liver Fibrosis (ELF), Steatosis-Associated Fibrosis Estimator (SAFE), LiverRisk Score (LRS), and Cirrhosis Outcome Risk Estimator (CORE)—were evaluated using pre-specified cut-offs (ELF ≥9.8, SAFE ≥100, LRS ≥10, CORE ≥5%). The primary endpoint was liver stiffness measurement (LSM) ≥8 kPa. Diagnostic performance, number needed to screen (NNS), and screening efficiency—defined as the balance between case detection and referral burden—were assessed. Paired bootstrap resampling was used to compare strategies.

Results

Among 2,488 screened individuals, 513 (21%) had indeterminate FIB-4, of whom 411 underwent VCTE (82% attendance rate). Elevated LSM (≥8 kPa) was present in 77 (18.7%). All NITs showed modest correlation with VCTE but consistent stepwise increases across LSM categories (<8 kPa, 8-12 kPa, >12 kPa). ELF achieved the highest diagnostic accuracy (AUC 0.74), although differences between tests were not statistically significant. As a standalone strategy, ELF maximized case detection but resulted in substantial over-referral (47% positive; 71% false positives), whereas LRS and CORE reduced referral rates (9–10%) at the expense of higher false negatives (16–17%). SAFE provided the most balanced performance. ELF and SAFE showed the lowest NNS to detect one case (7–8), while LRS and CORE required substantially more screening (NNS: 25–32). Combined testing improved performance: an ELF+SAFE strategy achieved 58% sensitivity, 89% specificity, 55% positive predictive value, 91% negative predictive value, and correctly classified 84% of individuals. This approach yielded the lowest inefficiency gap between NNS for referral and case detection.

Conclusion

In individuals with indeterminate FIB-4 from primary care, sequential and combined NIT strategies reveal a clear trade-off between over-referral and missed cases. While ELF maximizes sensitivity and LRS/CORE improve specificity, SAFE provides the most balanced standalone performance. A combined ELF+SAFE strategy optimizes screening efficiency by improving case detection while reducing unnecessary referrals, supporting its use as a pragmatic second-line approach in real-world care pathways.

References

1. European Association for the Study of the Liver, European Association for the Study of Diabetes. European Association for the Study of Obesity. EASL-EASD- EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024; 81:492–542.
2. Johansen S, Åberg F, Tsochatzis EA, Krag A. Screening for advanced steatotic liver disease. Lancet Gastroenterol Hepatol. 2025;10(9):842-854. doi:10.1016/S2468-1253(25)00097-4.

Event

UEG Week Barcelona 2026

Topics

Primary Care Hepatobiliary

Submission format

Abstract

Session

Steatotic liver disease: From screening and stigma to therapy

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano

SHORT-TERM GAINS, LONG-TERM CHALLENGES: A PILOT RANDOMIZED CONTROLLED TRIAL FOR TIME-RESTRICTED FEEDING VERSUS CALORIC RESTRICTION IN SIGNIFICANT MASLD

Dan Yock Young

OPTIMIZING SCREENING STRATEGIES FOR REFERRAL OF ADVANCED STEATOTIC LIVER DISEASE FROM PRIMARY CARE

Paloma Lluch García

ENDOSCOPIC FEATURES OF HELICOBACTER PYLORI INFECTION: DIFFERENCES BETWEEN PPI-USERS AND NO USERS

Guido Manfredi

EFFICACY AND SAFETY OF ELOBIXIBAT COMPARED WITH VITAMIN E IN ADULTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE: A 12-WEEK RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL

Irsan Hasan

CELIAC INSIDER WEBSITE AS A TOOL TO IMPROVE CELIAC DISEASE DIAGNOSIS

Mercè Tena

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

ENDOSCOPIC FEATURES OF HELICOBACTER PYLORI INFECTION: DIFFERENCES BETWEEN PPI-USERS AND NO USERS

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

ENDOSCOPIC FEATURES OF HELICOBACTER PYLORI INFECTION: DIFFERENCES BETWEEN PPI-USERS AND NO USERS

Mario Capasso 1, Michael Visentin 1, Samanta Romeo 1, Roberto Bertè 1, Flavio Metelli 1, Antonio Cerrone 1, Stefania Bertolazzi 1, Simona Albano 1, Saverio Alicante 1, Claudio Londoni 1, Guido Manfredi 1

Affiliations

1 ASST MAggiore Hospital Cema, Crema (CR), Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Helicobacter pylori (H. pylori) infection is one of the most prevalent chronic bacterial infections worldwide [1]. Several endoscopic signs may predict H. pylori status [2]. However, literature lacks data regarding endoscopic differences based on proton pump inhibitors (PPIs) assumption.

Aims & Methods

Aim of this study is to describe the endoscopic differences between PPI-user patients and no users.
This was a monocentric prospective study including all consecutive outpatients who underwent upper-GI endoscopy in one-year timeline. After enrollment, patients were divided in two groups: no-PPI users (group A) and on-PPI patients (group B). Each procedure was performed by trained endoscopists in order to describe regular arrangement collecting venules (RAC), fundic gland polyps (FGPs), linear streaks, hematin spots and diffuse redness. H. pylori infection was histologically investigated.

Results

A total of 680 patients were enrolled (F: 373, 54.9%), according to inclusion criteria, median age was 57.3 y.o. (IQR 45.4-68.5). Group A included 421 patients, group B 259 patients. Comparing the two groups, the prevalence of H. pylori was 80 (19%) in group A and 37 (14.3%) in group B (p=0.1). RAC on both the greater and lesser curvatures was more frequently observed in group A (287, 68.1% vs 148, 57.1%, p=0.004 and 275, 65.3% vs 134, 51.7%, p<0.001). The presence of FGPs is less frequent in group A than in group B (72, 17.1% vs 73, 28.1%, p<0.001). Hematin spots were more represented in group A (58, 13.7% vs 13, 5.1%, p<0.001). Diffuse redness was more frequent in group A than in group B (54, 12.8% vs 9, 3.5%, p<0.0001). No differences were found in linear streaks observation between the two groups (A: 58, 13.7% vs B: 47, 18.1%, p= 0.06). At multivariable analysis in group A, RAC on lesser curvature and FGPs was significantly associated with H. pylori-negative status (OR 0.05, 95% CI: 0.02–0.13, and OR 0.11, 95% CI: 0.03–0.53, respectively; p<0.001). Nonetheless, in group B, FGPs lost statistical significance (OR 0.45, 95% CI: 0.14–1.45, p=0.1), the presence of RAC on the greater curvature is inversely associated with H. pylori infection (OR 0.04, 95% CI: 0.01–0.23, p<0.001), while hematin spots and diffuse redness became significantly associated with H. pylori-positive status (OR 20.7, 95% CI: 3.07–139.65; and OR 13.8, 95% CI: 2.39–80.26, respectively; p<0.003).

Conclusion

The presence of RAC represents a feature significantly associated with H. pylori-negative status. However, FGPs may be considered a reliable marker of H. pylori-negative status only in the no-PPI users, whereas PPI use may increase the prevalence of FGPs, thereby making this feature less dependable. In the on-PPI population, the recognition of hematin spots and diffuse redness may be regarded as cornerstones in the endoscopic prediction of H. pylori-positive status.

References

Chen YC, et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology 2024
Seo J, et al. Predicting Helicobacter pylori infection from endoscopic features. KJIM, 2024

Event

UEG Week Barcelona 2026

Topics

Stomach & H. Pylori Oesophagus

Submission format

Abstract

Session

Anti-secretory therapy: Evolving standards and future horizons

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano

SHORT-TERM GAINS, LONG-TERM CHALLENGES: A PILOT RANDOMIZED CONTROLLED TRIAL FOR TIME-RESTRICTED FEEDING VERSUS CALORIC RESTRICTION IN SIGNIFICANT MASLD

Dan Yock Young

OPTIMIZING SCREENING STRATEGIES FOR REFERRAL OF ADVANCED STEATOTIC LIVER DISEASE FROM PRIMARY CARE

Paloma Lluch García

ENDOSCOPIC FEATURES OF HELICOBACTER PYLORI INFECTION: DIFFERENCES BETWEEN PPI-USERS AND NO USERS

Guido Manfredi

EFFICACY AND SAFETY OF ELOBIXIBAT COMPARED WITH VITAMIN E IN ADULTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE: A 12-WEEK RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL

Irsan Hasan

CELIAC INSIDER WEBSITE AS A TOOL TO IMPROVE CELIAC DISEASE DIAGNOSIS

Mercè Tena

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

EFFICACY AND SAFETY OF ELOBIXIBAT COMPARED WITH VITAMIN E IN ADULTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE: A 12-WEEK RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

EFFICACY AND SAFETY OF ELOBIXIBAT COMPARED WITH VITAMIN E IN ADULTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE: A 12-WEEK RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL

Cosmas Rinaldi A Lesmana 1,2, Sharon Sandra 3, Anita Kurnia Ilahi 3, Gita Aprilicia 3, Irsan Hasan 1

Affiliations

1 Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia

2 Medistra Hospital, Jakarta, Indonesia

3 Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Metabolic associated steatotic liver disease (MASLD) has become the emerging cause of chronic liver disease worldwide. However, treatment options remain limited with lifestyle intervention is still the standard of care.¹ Elobixibat, a selective ileal bile acid transporter inhibitor, increases faecal bile acid excretion² and has been associated with improvement lipid and glucose metabolism.^3,4 Its effects on liver steatosis and fibrosis in human remain is still unclear.

Aims & Methods

This was a randomized controlled trial (RCT) assessed the short-term hepatic and metabolic effects of elobixibat compared with vitamin E in adults with MASLD. Adult patients with hepatic steatosis underwent transient elastography examination using FibroScan by Echosens (controlled attenuation parameter (CAP) >260 dB/m) were randomized into three groups: elobixibat 10 mg daily, elobixibat 15 mg daily, or vitamin E 400 mg daily for 12 weeks. Primary outcomes were changes in CAP and liver stiffness measurement (LSM). Secondary outcomes included Fibrosis-4 Index (FIB-4), alanine aminotransferase (ALT), creatinine, lipid profile, and fasting glucose. Both within-group changes and between-group comparisons at week 12 were analysed using appropriate tests.

Results

A total 85 patients completed the treatment arms, where 30 patients received vitamin E 400mg cap once daily, 25 patients received elobixibat 10 mg tablet once daily, and 30 patients recieved elobixibat 15 mg once daily. Baseline demographic, metabolic, dietary, and physical activity characteristics were comparable across groups.
At week 12, CAP showed improvement in the Vitamin E group (310 to 297 dB/m; p=0.202) and elobixibat 10 mg (309 dB/m to 284 dB/m; p=0.083), but not in the elobixibat 15 mg group (302 dB/m to 304 dB/m; p=0.758). LSM significantly improved in elobixibat 15 mg group (6,5 to 5,7 kPa; p=0,017, while favourable trends were seen with vitamin E (5,9 to 4,9 kPa; p=0,178) and elobixibat 10 mg (6,9 to 5,7 kPa; p=0,081). Categorized LSM (F2-F4 vs F0-F1) improved significantly in all groups (vitamin E p=0,031; elobixibat 10 mg p =0,016; elobixibat 15 mg p=0,021).
No significant change was observed in FIB-4, ALT, creatinine, lipid profile, and fasting glucose between groups. Adverse events were more frequent with elobixibat (vitamin E 16,7%, elobixibat 10 mg 44%, elobixibat 15 mg 60%; p=0,003), predominantly was the increased of bowel frequency.

Conclusion

Elobixibat treatment showed a promising short-term effect on liver stiffness improvement, with statistically significant LSM at the 15 mg dose and favourable fibrosis-stage shift across treatment arms. CAP reduction appeared greatest with the 10 mg dose. Treatment was generally well tolerated, although gastrointestinal adverse events were more common in the elobixibat groups. Larger and longer duration studies are warranted to confirm its role in MASLD management.

References

European Association for the Study of the Liver, European Association of the Study of Diabetes, European Association for the Study of Obesity. Tacke F, Horn P, Wai-Sun Wong V, et al. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024; 81:492-542
Nakajima A, Ishizaki S, Matsuda K, et al. Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation. J Gastroenterol Hepatol. 2022 May;37(5):883-890.
Matsuyama M, Hirai K, Nonaka H, et al. Effects of elobixibat on constipation and lipid metabolism in patients with moderate to end-stage chronic kidney disease. Front Med. 2022;8:780127.
Hishida Y, Nagai Y, Tsukiyama H, et al. Effects of elobixibat in patients with diabetes and concomitant chronic constipation: an 8-week, prospective, single-center, single-arm study. Adv Ther. 2022 Sep;39(9):4205-4217.

Disclosure

Nothing to disclose

Event

UEG Week Barcelona 2026

Topics

Primary Care Hepatobiliary

Submission format

Abstract

Session

Steatotic liver disease: From screening and stigma to therapy

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano

SHORT-TERM GAINS, LONG-TERM CHALLENGES: A PILOT RANDOMIZED CONTROLLED TRIAL FOR TIME-RESTRICTED FEEDING VERSUS CALORIC RESTRICTION IN SIGNIFICANT MASLD

Dan Yock Young

OPTIMIZING SCREENING STRATEGIES FOR REFERRAL OF ADVANCED STEATOTIC LIVER DISEASE FROM PRIMARY CARE

Paloma Lluch García

ENDOSCOPIC FEATURES OF HELICOBACTER PYLORI INFECTION: DIFFERENCES BETWEEN PPI-USERS AND NO USERS

Guido Manfredi

EFFICACY AND SAFETY OF ELOBIXIBAT COMPARED WITH VITAMIN E IN ADULTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE: A 12-WEEK RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL

Irsan Hasan

CELIAC INSIDER WEBSITE AS A TOOL TO IMPROVE CELIAC DISEASE DIAGNOSIS

Mercè Tena

UEG Poster

New

Audio / Video Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

CELIAC INSIDER WEBSITE AS A TOOL TO IMPROVE CELIAC DISEASE DIAGNOSIS

Bianca den Drijver 1, Martin Brandenburg 1, Elisa Sormani 1, Mercè Tena 1

Affiliations

1 Immunodiagnostics Division, Thermo Fisher Scientific, Freiburg, Germany

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Diagnosing celiac disease (CeD) poses significant challenges for healthcare professionals (HCPs) due to its diverse symptoms that often overlap with other gastrointestinal disorders. This leads to prolonged diagnosis times and impaired patient quality of life.

Aims & Methods

Aim: Our goal was to create an online platform to empower patients to get tested and raise awareness among HCPs to shorten the time to diagnosis of celiac disease.
Materials and Methods: Developed by Thermo Fisher Scientific (TFS), the website celiac insider was launched in English in November 2022. The site was promoted through SEM, social media and influencer campaigns. French and German versions were released in May 2024, with Italian and Spanish versions launched in October 2025.

Results

Celiac insider provides essential evidence-based resources to facilitate accurate diagnosis and support patients. It includes downloadable tools such as a food diary, symptom tracker, and brochures tailored for both audiences.
Since the introduction of the multilingual versions of the website, the website has received more than 900,000 unique visits from more than 150 countries with an average visit time of 1 minute 36 seconds and 1:6 repeated visitors. As of May 2024, the French and German versions have received over 350,000 unique visits, respectively. The Italian and Spanish versions have received over 98,000 unique visitors (Italian site) and over 33,000 unique visitors (Spanish site) since their launch in October 2025. With the addition of new language versions, we aim to broaden accessibility and increase reach among patients and HCP’s across diverse geographic regions.

*Current as of end of April 2026

Conclusion

Celiac insider demonstrates that a multilingual digital platform can effectively engage a global audience and disseminate evidence-based information on CeD. Such tools may support earlier recognition and testing, potentially contributing to a reduced diagnostic delay.

Disclosure

Nothing

Conference

UEG Week Barcelona 2026

Topics

Small Intestine & Nutrition

Submission format

Abstract

Session

SMALL INTESTINAL (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Targeting immunometabolism with medical therapies in IBD

Virginia Solitano

SHORT-TERM GAINS, LONG-TERM CHALLENGES: A PILOT RANDOMIZED CONTROLLED TRIAL FOR TIME-RESTRICTED FEEDING VERSUS CALORIC RESTRICTION IN SIGNIFICANT MASLD

Dan Yock Young

OPTIMIZING SCREENING STRATEGIES FOR REFERRAL OF ADVANCED STEATOTIC LIVER DISEASE FROM PRIMARY CARE

Paloma Lluch García

ENDOSCOPIC FEATURES OF HELICOBACTER PYLORI INFECTION: DIFFERENCES BETWEEN PPI-USERS AND NO USERS

Guido Manfredi

EFFICACY AND SAFETY OF ELOBIXIBAT COMPARED WITH VITAMIN E IN ADULTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE: A 12-WEEK RANDOMIZED DOUBLE BLIND CONTROLLED TRIAL

Irsan Hasan

CELIAC INSIDER WEBSITE AS A TOOL TO IMPROVE CELIAC DISEASE DIAGNOSIS

Mercè Tena